The technology sector is loaded with big megacap stocks that dominate their industry. However, if there is one mid-cap stock that could emerge to become one of the most important tech stocks by 2028, ...

UiPath has flown under the media's radar despite some heavy Wall Street investment late last year, is it worth a look?

Despite my piece lambasting AI agent (over)hype, I am not anti-agent, even if "agentic" is low on my list of favorite buzzwords. I'm just pushing for more precision on the pros and cons - and use case ...

UiPath's robust AI-driven automation platform, strong earnings beats, and 16% YoY revenue growth highlight its upward trajectory. Read why PATH stock is a strong buy.

In boardrooms and IT departments alike, a hard truth is setting in: most so-called “smart assistants” aren’t built for the messy, unpredictable world of the enterprise. While conversational bots and ...

UiPath looks like a better buy than market leader Palantir Technologies.

WASHINGTON, D.C. / ACCESS Newswire / September 30, 2025 / AGS Health, a leading provider of tech-enabled revenue cycle management (RCM) solutions and a strategic growth partner to healthcare providers ...

UiPath aims to lead the RPA market by integrating advanced AI solutions, differentiating itself from competitors like Automation Anywhere and Blue Prism. Strategic partnerships with tech giants like ...